These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38743091)

  • 1. Sublingual apomorphine in the treatment of Parkinson's disease.
    Kassubek J; Jost WH; Schwarz J
    J Neural Transm (Vienna); 2024 Oct; 131(10):1209-1216. PubMed ID: 38743091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sublingual apomorphine in treatment of Parkinson's disease: a review.
    Hislop J; Margolesky J; Shpiner DS
    Int J Neurosci; 2024 May; 134(5):474-480. PubMed ID: 35986574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
    Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
    J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
    Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
    Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On demand therapy for Parkinson's disease patients: Opportunities and choices.
    Hauser RA; LeWitt PA; Comella CL
    Postgrad Med; 2021 Sep; 133(7):721-727. PubMed ID: 34082655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
    Stocchi F; Rascol O; Poewe W; Chaudhuri KR; Kassubek J; Lopez Manzanares L; Zhang Y; Bowling A; Pappert E; Wu S;
    J Parkinsons Dis; 2023; 13(8):1329-1342. PubMed ID: 37980683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On-Demand Therapy for OFF Episodes in Parkinson's Disease.
    Olanow CW; Poewe W; Rascol O; Stocchi F
    Mov Disord; 2021 Oct; 36(10):2244-2253. PubMed ID: 34363424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
    Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
    Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease.
    Nasser A; Gomeni R; Ceresoli-Borroni G; Xie L; Busse GD; Melyan Z; Rubin J
    J Pharmacokinet Pharmacodyn; 2024 Aug; 51(4):385-393. PubMed ID: 38578533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease.
    Olanow CW; Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Navia B
    Parkinsonism Relat Disord; 2021 Dec; 93():27-30. PubMed ID: 34763305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.
    Antonini A; Nitu B
    J Neural Transm (Vienna); 2018 Aug; 125(8):1131-1135. PubMed ID: 30006821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhaled levodopa: from evidence to experience].
    Martínez-Castrillo JC; Pareés-Moreno I; López Sendón-Moreno JL; Pérez-Torre P; Fanjul S; Patiño-Patón A; García-Ribas G; Alonso-Cánovas A
    Rev Neurol; 2024 Jun; 78(S01):S1-S10. PubMed ID: 38916176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apomorphine hydrochloride for the treatment of Parkinson's disease.
    Unti E; Ceravolo R; Bonuccelli U
    Expert Rev Neurother; 2015; 15(7):723-32. PubMed ID: 26037961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sublingual apomorphine (Kynmobi) for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Oct; 62(1609):165-166. PubMed ID: 33429410
    [No Abstract]   [Full Text] [Related]  

  • 15. Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease.
    Agbo F; Crass RL; Chiu YY; Chapel S; Galluppi G; Blum D; Navia B
    Clin Transl Sci; 2021 Jul; 14(4):1464-1475. PubMed ID: 33650272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease 'OFF' episodes.
    Caughman CY; Factor S
    Expert Rev Neurother; 2021 Feb; 21(2):169-177. PubMed ID: 33227223
    [No Abstract]   [Full Text] [Related]  

  • 17. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease.
    Ondo W; Hunter C; Almaguer M; Jankovic J
    Mov Disord; 1999 Jul; 14(4):664-8. PubMed ID: 10435505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
    Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
    J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
    Hui JS; Fox SH; Neeson W; Bhargava P; Pappert E; Blum D; Navia B;
    Parkinsonism Relat Disord; 2020 Oct; 79():110-116. PubMed ID: 32927285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.